Vadim Sapiro - OpGen Chief Officer
| OPGN Stock | USD 3.06 0.35 10.26% |
Executive
Mr. Vadim Sapiro serves as Chief Information Officer of the Company. He joined the Company in December, 2011 as Chief Information Officer. Mr. Sapiro is responsible for leading the development of the Company bioinformatics applications, software, databases and information technology operations. Prior to OpGen, Mr. Sapiro was senior vice president at SAICFrederick, or SAIC, from June 2008 to December 2011, overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among Mr. Sapiro projects were technical program management and operations for the cancer Biomedical Informatics Grid, the cancer Human Biobank and The Cancer Genome Atlas . Prior to SAIC, from July 1999 to May 2008, Mr. Sapiro was Vice President for Information Technology with the J. Craig Venter Institute. Mr. Sapiro is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees since 2011.
| Age | 53 |
| Tenure | 13 years |
| Address | 9717 Key West Avenue, Rockville, MD, United States, 20850 |
| Phone | 240 813 1260 |
| Web | https://www.opgen.com |
OpGen Management Efficiency
The company has return on total asset (ROA) of (0.4491) % which means that it has lost $0.4491 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1492) %, meaning that it created substantial loss on money invested by shareholders. OpGen's management efficiency ratios could be used to measure how well OpGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of June 2024, Return On Tangible Assets is likely to drop to -1.89. In addition to that, Return On Capital Employed is likely to drop to -2.14. At this time, OpGen's Non Currrent Assets Other are very stable compared to the past year. As of the 3rd of June 2024, Other Assets is likely to grow to about 3.4 M, while Total Assets are likely to drop about 21.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kimberly Bambach | Tivic Health Systems | 52 | |
| John Kowalczyk | Nuwellis | N/A | |
| Stephen JD | Sight Sciences | N/A | |
| Amir Rippel | NanoVibronix | N/A | |
| Stephanie Huebner | Vivos TherapeuticsInc | N/A | |
| Tom Huang | Sight Sciences | N/A | |
| Yafit Tehila | Inspira Technologies Oxy | 41 | |
| Marc MD | enVVeno Medical Corp | 75 | |
| Eryn Graham | Bluejay Diagnostics | N/A | |
| Les DeLuca | Bluejay Diagnostics | N/A | |
| Robert Bowdring | INVO Bioscience | 66 | |
| Ryan McSeveney | Bluejay Diagnostics | N/A | |
| Vitaliy Epshteyn | Nuwellis | 46 | |
| FACC MD | Nuwellis | N/A | |
| Lindsey Harrison | NanoVibronix | N/A | |
| Meshira Greenberg | Inspira Technologies Oxy | N/A | |
| Ruth Hembree | Vivos TherapeuticsInc | N/A | |
| Thomas Stankovich | ReShape Lifesciences | 63 | |
| Irene Thomas | Neuropace | 55 | |
| Robert Scott | Nuwellis | 44 | |
| Matthew Link | Sight Sciences | 49 | |
Management Performance
| Return On Equity | -3.15 | ||||
| Return On Asset | -0.45 |
OpGen Inc Leadership Team
Elected by the shareholders, the OpGen's board of directors comprises two types of representatives: OpGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OpGen. The board's role is to monitor OpGen's management team and ensure that shareholders' interests are well served. OpGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OpGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Albert Weber, CFO Secretary | ||
| Michael Farmer, VP Marketing | ||
| Arne Materna, MD GmbH | ||
| Terrance Walker, Sr. VP of RandD | ||
| Derek Joesting, VP Sales | ||
| Vadim Sapiro, Chief Officer | ||
| Faranak Atrzadeh, Chief Officer | ||
| Theo deVos, MD Genetics | ||
| David Lazar, CEO Chairman | ||
| Johannes Bacher, Chief Officer | ||
| Oliver Schacht, Executive Development |
OpGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OpGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.15 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (5.10) % | ||||
| Current Valuation | 15.32 M | ||||
| Shares Outstanding | 1.26 M | ||||
| Shares Owned By Insiders | 5.14 % | ||||
| Shares Owned By Institutions | 3.68 % | ||||
| Number Of Shares Shorted | 77.75 K | ||||
| Price To Earning | (0.39) X | ||||
| Price To Book | 3.01 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OpGen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the OpGen Inc information on this page should be used as a complementary analysis to other OpGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for OpGen Stock analysis
When running OpGen's price analysis, check to measure OpGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OpGen is operating at the current time. Most of OpGen's value examination focuses on studying past and present price action to predict the probability of OpGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OpGen's price. Additionally, you may evaluate how the addition of OpGen to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is OpGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OpGen. If investors know OpGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OpGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (62.50) | Revenue Per Share 5.476 | Quarterly Revenue Growth 0.558 | Return On Assets (0.45) | Return On Equity (3.15) |
The market value of OpGen Inc is measured differently than its book value, which is the value of OpGen that is recorded on the company's balance sheet. Investors also form their own opinion of OpGen's value that differs from its market value or its book value, called intrinsic value, which is OpGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OpGen's market value can be influenced by many factors that don't directly affect OpGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OpGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if OpGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OpGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.